Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique

被引：0
|
作者：
Bonny Parkinson
Sallie-Anne Pearson
Rosalie Viney
机构：
[1] University of Technology,Centre for Health Economics Research and Evaluation (CHERE)
[2] Sydney,Pharmacoepidemiology and Pharmaceutical Policy Research Group, Faculty of Pharmacy
[3] The University of Sydney,undefined
来源：
The European Journal of Health Economics | 2014年 / 15卷
关键词：
Economics; Cost-utility analysis; Cost-effectiveness analysis; Breast neoplasms; Metastatic; Trastuzumab; I18; D61;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：93 / 112
页数：19
相关论文
共 50 条
  • [21] Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
    R Y Tsang
    R S Finn
    British Journal of Cancer, 2012, 106 : 6 - 13
  • [22] Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
    Mateus de Oliveira Taveira
    Sheida Nabavi
    Yuker Wang
    Peter Tonellato
    Francisco J. Esteva
    Lewis C. Cantley
    Gerburg M. Wulf
    Journal of Cancer Research and Clinical Oncology, 2017, 143 : 1255 - 1262
  • [23] Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer
    Mark Sanford
    Targeted Oncology, 2014, 9 : 85 - 94
  • [24] Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer
    Sanford, Mark
    TARGETED ONCOLOGY, 2014, 9 (01) : 85 - 94
  • [25] Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
    Tsang, R. Y.
    Finn, R. S.
    BRITISH JOURNAL OF CANCER, 2012, 106 (01) : 6 - 13
  • [26] Duration of trastuzumab in patients with HER2-positive metastatic breast cancer in prolonged remission
    Haq, R.
    Gulasingam, P.
    CURRENT ONCOLOGY, 2016, 23 (02) : 91 - 95
  • [27] Effect of Adjuvant/Neoadjuvant Trastuzumab on Clinical Outcomes in Patients With HER2-Positive Metastatic Breast Cancer
    Murthy, Rashmi K.
    Varma, Ankur
    Mishra, Priyankana
    Hess, Kenneth R.
    Young, Elliana
    Murray, James L.
    Koenig, Kimberly H.
    Moulder, Stacy L.
    Melhem-Bertrandt, Amal
    Giordano, Sharon H.
    Booser, Daniel
    Valero, Vicente
    Hortobagyi, Gabriel N.
    Esteva, Francisco J.
    CANCER, 2014, 120 (13) : 1932 - 1938
  • [28] Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
    Madden, Rebecca
    Kosari, Sam
    Peterson, Gregory M.
    Bagheri, Nasser
    Thomas, Jackson
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2018, 56 (02) : 72 - 80
  • [29] 'Simply stunning' - trastuzumab in HER2-positive breast cancer
    Doggrell, SA
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (05) : 631 - 634
  • [30] The art of prescribing trastuzumab for HER2-positive breast cancer
    Outhoff, K.
    SOUTHERN AFRICAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2011, 3 (01) : 16 - 26
12345